vTv Secures 20-Year Patent Protection for First-in-Class Type 1 Diabetes Drug Cadisegliatin – Stock Titan

vTv Secures 20-Year Patent Protection for First-in-Class Type 1 Diabetes Drug Cadisegliatin  Stock Titan